-1753360571959.webp&w=3840&q=75)
2025 NOSCM | Immunotherapy in First Line Metastatic Setting
0% Complete
Course Overview
Dr. Eric Singhi reviewed immunotherapy in first-line metastatic settings, noting 30% five-year survival for PDL1 high patients.
Course Content
Credits
- AMA PRA Category 1 Credit™Non-CME
Course Details
- Duration
- 0.00 hour
- Released
- Jul 25, 2025
- Last Review
- Jul 25, 2025
- Expires
- Jul 25, 2026
Target Audience
Physicians
Nurses
Pharmacists
Physician Associates
Faculty & Disclosure
Faculty
Eric K. Singhi, MD
Accreditation
NA
